Genmab A/S remains a subject of much debate in the investing world. It's cited heavily amongst high growth, large cap stocks to buy now, despite enduring a substantial 42% loss over the last three years. Rather impressively,
Genmab's revenue surged by 18% in Q3. However, the company remains amongst the worst-performing biotech stocks in 2024. Despite this, its potential for innovation in antibody therapeutics is recognized, benefitting from a boost in trading and discussion regarding the stock's potential being undervalued. Short interest has recently decreased, suggesting increased confidence. Future strategies include a capital expansion plan by 2029, with an attention-grabbing $1.8 billion deal underway.
Genmab's strong H1 2024 performance and discussions regarding attractive financial prospects, somewhat counters the underlying caution signalled by insider selling of stocks. Nevertheless, the company's potential for growth is recognized, with a focus on near term earnings and Q3 Darzalex sales reportedly over $3 billion. However, there are concerns over a legal battle with J&J over a cancer drug.
Genmab Stocks News Analytics from Mon, 19 Aug 2019 07:00:00 GMT to Thu, 02 Jan 2025 06:29:10 GMT -
Rating -1
- Innovation 4
- Information 3
- Rumor -2
